Athira Pharma, Inc.
ATHA
$0.3848
$0.00481.26%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 22.63M | 24.88M | 26.09M | 26.86M | 27.13M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 57.89M | 78.62M | 96.78M | 111.85M | 121.40M |
Operating Income | -57.89M | -78.62M | -96.78M | -111.85M | -121.40M |
Income Before Tax | -59.85M | -79.75M | -96.94M | -109.22M | -113.45M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -59.85 | -79.75 | -96.94 | -109.22 | -113.45 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -59.85M | -79.75M | -96.94M | -109.22M | -113.45M |
EBIT | -57.89M | -78.62M | -96.78M | -111.85M | -121.40M |
EBITDA | -56.92M | -77.65M | -95.81M | -110.88M | -120.43M |
EPS Basic | -1.55 | -2.07 | -2.52 | -2.85 | -2.97 |
Normalized Basic EPS | -0.90 | -1.23 | -1.51 | -1.75 | -1.89 |
EPS Diluted | -1.55 | -2.07 | -2.52 | -2.85 | -2.97 |
Normalized Diluted EPS | -0.90 | -1.23 | -1.51 | -1.75 | -1.89 |
Average Basic Shares Outstanding | 155.36M | 154.64M | 153.92M | 153.32M | 152.86M |
Average Diluted Shares Outstanding | 155.36M | 154.64M | 153.92M | 153.32M | 152.86M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |